Paul Tudor Jones II's position in Immunovant is currently worth $2.27 Million. That's 0.03% of their equity portfolio (600th largest holding). The first Immunovant trade was made in Q1 2023. Since then Paul Tudor Jones II bought shares two more times and sold shares on two occasions. The investor's estimated purchase price is $3.2 Million, resulting in a loss of 29%.